# Ubrelvy (ubrogepant) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ubrogepant

> The FDA approved Ubrelvy (ubrogepant), sponsored by AbbVie Inc. (ABBV), on December 23, 2019.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ubrelvy (ubrogepant) |
| Codes |  |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [Migraine](https://sec-api.dev/indications/migraine) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 23, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211765 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191223, review_priority STANDARD; sponsor_name ABBVIE; product UBRELVY (UBROGEPANT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211765%22

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05125302 (Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05125302

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05125302 (Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05125302

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06417775 (Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06417775

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06417775 (Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT06417775

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05127954 (Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05127954

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05127954 (Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT05127954

## Same indication

- [Qulipta (atogepant)](https://sec-api.dev/pdufa/atogepant) (ABBV)
- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab) (AMGN)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab) (TEVA)
- [Reyvow (lasmiditan succinate)](https://sec-api.dev/pdufa/lasmiditan) (LLY)
- [MEDI0618](https://sec-api.dev/pdufa/medi0618) (ABBV)
- [Nurtec Odt (rimegepant sulfate)](https://sec-api.dev/pdufa/rimegepant) (PFE)
- [Zavzpret ® (zavegepant)](https://sec-api.dev/pdufa/zavegepant) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ubrogepant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ubrelvy (ubrogepant) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ubrogepant

```bibtex
@misc{secapidev_pdufa_ubrogepant_20261116,
  title        = {Ubrelvy (ubrogepant) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ubrogepant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ubrogepant_20261116","title":"Ubrelvy (ubrogepant) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ubrogepant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
